Status
Acquired by Cephalon on March 21, 2011
Funding Received
$71.3 Million in 4 Rounds from 13 Investors
Founded:
1998
Headquarters:
Montréal, QC
Description:
Gemin X Pharmaceuticals develops and commercializes targeted cancer therapeutics to improve the lives of patients.
Founders:
Gordon C. Shore
Categories:
Biotechnology
Website:
http://www.geminx.com

Detailed Description

Update

Gemin X Pharmaceuticals is dedicated to the discovery, development and commercialization of novel, targeted cancer therapeutics to improve the lives of patients.

Gemin X's research on the Bcl-2 cell death regulation pathway has led to the discovery of GX15-070 (obatoclax), a novel small molecule that selectively reinitiates programmed cell death, or apoptosis, and may also be effective in inducing cancer cell self-digestion, or autophagy. Obatoclax has shown promising activity in both preclinical and early human clinical studies and is currently in Phase 2 clinical trials as both a single agent and combination therapy. Obatoclax has patent protection through 2025.

Current Team (4)

Update

Past Team (1)

Update

Investors (13)

Update

Offices/Locations (1)

Update
  • Office

    3576 Avenue du Parc

    Suite 4310, QC

    Montréal, QC H2X 2H7

    CAN

Images (1)

Update
  • Cd32ff7b5f0d0474d74f74b2db68b3ea